Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

216
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
216
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

493
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
493
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

6.1K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.1K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

1.9K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.9K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

404
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
404
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

3.9K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systematic review on the safety and effectiveness of restorative therapies for erectile dysfunction.

The journal of sexual medicine·2026
Same author

Effects and mechanism of low-intensity pulsed ultrasounds on testicular steroidogenesis in rats.

Asian journal of andrology·2026
Same author

Correction: Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.

PloS one·2026
Same author

Vasectomy reversal: lessons learned to optimize clinical outcomes.

International journal of impotence research·2026
Same author

Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.

PloS one·2026
Same author

The development of an advanced lentiviral gene therapy for beta-thalassemia.

Biochemical and biophysical research communications·2025

Related Experiment Video

Updated: Jan 2, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

728

Improving erectile function by silencing phosphodiesterase-5.

Guiting Lin1, Narihiko Hayashi, Rafael Carrion

  • 1Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California-San Francisco 94143-1695, USA.

The Journal of Urology
|August 12, 2005
PubMed
Summary
This summary is machine-generated.

Small interfering RNA (siRNA) effectively reduced phosphodiesterase-5 (PDE5) in rats, leading to prolonged cyclic guanosine monophosphate (cGMP) accumulation and improved erectile function. This study demonstrates a novel therapeutic approach for erectile dysfunction.

More Related Videos

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
02:21

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Published on: March 15, 2024

1.3K
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.8K

Related Experiment Videos

Last Updated: Jan 2, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

728
Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
02:21

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Published on: March 15, 2024

1.3K
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.8K

Area of Science:

  • Molecular Biology
  • Urology
  • Pharmacology

Background:

  • Phosphodiesterase-5 (PDE5) is a key enzyme regulating smooth muscle relaxation and erectile function.
  • Dysregulation of PDE5 activity is implicated in erectile dysfunction.
  • Targeting PDE5 expression offers a potential therapeutic strategy for improving erectile function.

Purpose of the Study:

  • To investigate the down-regulation of PDE5 using small interfering RNA (siRNA).
  • To evaluate the impact of PDE5 down-regulation on erectile function in a rat model.

Main Methods:

  • A PDE5-specific siRNA construct (pPDE5-silencer) was developed and delivered via lentivirus into rat penises.
  • PDE5 expression was assessed in rat cavernous smooth muscle cells (CSMCs) and in vivo.
  • cGMP levels were measured after sodium nitroprusside (SNP) stimulation.
  • Erectile function was evaluated by electrostimulation and measurement of intracorporeal pressure.

Main Results:

  • Transfection with pPDE5-silencer significantly decreased PDE5 expression by 88.2% in CSMCs.
  • siRNA-treated cells exhibited prolonged high cGMP levels post-SNP stimulation compared to controls.
  • Rats treated with siRNA showed enhanced erectile function, indicated by increased peak intracorporeal pressure and pressure increase.
  • Reduced PDE5 expression was confirmed in the cavernous smooth muscle of siRNA-treated rats.

Conclusions:

  • siRNA-mediated down-regulation of PDE5 is achievable.
  • Reduced PDE5 expression leads to sustained cGMP accumulation.
  • This approach holds promise for improving erectile function and treating erectile dysfunction.